Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
S&P 500 Futures Decline In Premarket Trading; GXO Logistics, Celsius Holdings Lead
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Blueprint Medicines Insider Sold Shares Worth $324,500, According to a Recent SEC Filing
Investing in Blueprint Medicines (NASDAQ:BPMC) a Year Ago Would Have Delivered You a 74% Gain
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Stifel analyst Bradley Canino maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and maintains the target price at $155.According to TipRanks data, the analyst has a success rate of 45.3%
Blueprint Announces the Hiring of Industry Veteran John Smelter to Medical Outpatient Team
Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines Corporation's (NASDAQ:BPMC) Business Is Yet to Catch Up With Its Share Price
Blueprint Prep's Annual $20,000 Medical School Scholarship Now Open for Submissions
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC)
Blueprint Medicines (NASDAQ:BPMC) Has Debt But No Earnings; Should You Worry?
9 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Blueprint Medicines Insider Sold Shares Worth $3,905,872, According to a Recent SEC Filing
Analysts Just Shipped A Sizeable Upgrade To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)